Floatz logo

Onabotulinum Toxin A

Chronic Migraine

University of AlbertaPhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

106 Active assets in the Chronic Migraine cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Eptinezumab
Stanford University
Phase 4BBB

View all 50 →

Same molecule, other indications

Onabotulinum Toxin A is also rated in:

neuralgiaDormant
CCC
Indicative ·
53 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative ·
51 / 100
View asset →
Post-thoracotomy Pain SyndromeDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →